The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...
The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...
Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...
The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...
Among those with a chronic condition, concern of getting shingles is low with only 12% highly concerned and 37% somewhat concerned Over 80% of those with a chronic condition have not been informed by ...
Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...
The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.
Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.
The application was based on results from the three-arm Phase 3 CheckMate -8HW study.
Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback